Stock Events

Stock Events

Quince Therapeutics 

$1.31
53
+$0.17+15.11% Today

Statistics

Day High
1.36
Day Low
1.31
52W High
-
52W Low
-
Volume
1,044,213
Avg. Volume
-
Mkt Cap
72.94M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

19MayExpected
Q3 2025
Next
-1.56
-1.11
-0.66
-0.22
Expected EPS
-1.558
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-113.66MNet Income

Analyst Ratings

0Average Price Target
The highest estimate is 0.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow QNCX.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sangamo Therapeutics
SGMO
Mkt Cap104.07M
Sangamo Therapeutics, Inc. competes in the development of genomic therapies addressing a range of genetic disorders, similar to Quince Therapeutics' focus on regenerative medicines.
CRISPR Therapeutics
CRSP
Mkt Cap4.92B
CRISPR Therapeutics AG focuses on the development of gene-based medicines, including therapies for genetic diseases, competing in the same innovative healthcare space as Quince.
Editas Medicine
EDIT
Mkt Cap287.74M
Editas Medicine, Inc. works on editing genes to treat genetic diseases, directly competing with Quince's approach to addressing genetic disorders.
Intellia Therapeutics
NTLA
Mkt Cap1.59B
Intellia Therapeutics, Inc. is a leading developer of CRISPR/Cas9 gene-editing therapies for genetic diseases, making it a direct competitor in the genetic medicine field.
Voyager Therapeutics
VYGR
Mkt Cap222.9M
Voyager Therapeutics, Inc. specializes in the development of gene therapies for neurodegenerative diseases, competing in the broader market of genetic disorder treatments.
Protagonist Therapeutics
PTGX
Mkt Cap6.31B
Protagonist Therapeutics, Inc. is engaged in the discovery and development of novel peptide-based drugs, which could compete with Quince's therapeutic approaches in a broader sense.
Fate Therapeutics
FATE
Mkt Cap144.17M
Fate Therapeutics, Inc. is involved in the development of programmed cellular immunotherapies for cancer and immune disorders, competing in the innovative treatment space.
Regenxbio
RGNX
Mkt Cap454.19M
REGENXBIO Inc. focuses on the development, commercialization, and licensing of recombinant adeno-associated virus (AAV) gene therapy, which competes with Quince's focus on regenerative medicine and genetic therapies.

About

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
Show more...
CEO
ISIN
US22053A1079

Listings

XNAS
US
QNCX
BOATS
BOATS
QNCX.BOATS

0 Comments

Share your thoughts

FAQ

What is Quince Therapeutics stock price today?▼
The current price of QNCX.BOATS is $1.31 USD — it has increased by +15.11% in the past 24 hours. Watch Quince Therapeutics stock price performance more closely on the chart.
What is Quince Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Quince Therapeutics stocks are traded under the ticker QNCX.BOATS.
What is Quince Therapeutics market cap?▼
Today Quince Therapeutics has the market capitalization of 72.94M
When is the next Quince Therapeutics earnings date?▼
Quince Therapeutics is going to release the next earnings report on May 19, 2026.
What were Quince Therapeutics earnings last quarter?▼
QNCX.BOATS earnings for the last quarter are -0.25 USD per share, whereas the estimation was -0.22 USD resulting in a -16.28% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Quince Therapeutics revenue for the last year?▼
Quince Therapeutics revenue for the last year amounts to 0 USD.
What is Quince Therapeutics net income for the last year?▼
QNCX.BOATS net income for the last year is -113.66M USD.
In which sector is Quince Therapeutics located?▼
Quince Therapeutics operates in the Other sector.
When did Quince Therapeutics complete a stock split?▼
The last stock split for Quince Therapeutics was on April 13, 2026 with a ratio of 1:10.